LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Accueil・Liste d'Actions・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Fermé

28.71 0.35

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.72

Max

Chiffres clés
By Trading Economics
Revenu	43M 13M
Ventes	29M 107M
BPA	0.25
Marge bénéficiaire	12.139
Employés	524
EBITDA	16M 8.2M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+115.3% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	18M 1.5B
Ouverture précédente	28.36
Clôture précédente	28.71

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

27.895 / 30.16 Support & Résistance

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mai 2026, 22:27 UTC

Acquisitions, Fusions, Rachats

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mai 2026, 22:12 UTC

Résultats

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mai 2026, 21:52 UTC

Acquisitions, Fusions, Rachats

LVMH to Sell Marc Jacobs

15 mai 2026, 00:00 UTC

Résultats

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mai 2026, 23:57 UTC

Acquisitions, Fusions, Rachats

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mai 2026, 23:47 UTC

Résultats

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mai 2026, 23:47 UTC

Résultats

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mai 2026, 23:46 UTC

Résultats

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mai 2026, 23:46 UTC

Résultats

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mai 2026, 22:11 UTC

Acquisitions, Fusions, Rachats

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mai 2026, 22:00 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mai 2026, 21:55 UTC

Résultats

Nu Holdings 1Q EPS 18c >NU

14 mai 2026, 21:55 UTC

Résultats

Nu Holdings 1Q Rev $4.97B >NU

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

115.3% hausse

Prévisions sur 12 Mois

Moyen 62.33 USD 115.3%

Haut 100 USD

Bas 33 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

27.895 / 30.16Support & Résistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.